| Prev Close | 14.03 |
| Day Low/High | 13.61 / 14.89 |
| 52 Wk Low/High | 3.87 / 14.60 |
| Avg Volume | 2.05M |
TG Therapeutics Inc. (TGTX)
13.70
NASDAQ : Health Technology
| Exchange | NASDAQ |
| Shares Outstanding | 99.56M |
| Market Cap | 1.40B |
| EPS | -2.30 |
| P/E Ratio | N/A |
| Div & Yield | N.A. (N.A) |
Latest News
3 Small-Cap Biotech Stocks That Could Thrive in 2020
The trio of BioDelivery Sciences, Omeros and TG Therapeutics looks well-positioned to capitalize on their potential in the New Year.
2 Potential Targets as Biotech Acquisition Activity Heats Up
TG Therapeutics and Exelixis could find themselves on the shopping lists of other companies.
2 Small Biotech Stocks Spurt Ahead on Positive Developments
Heron Therapeutics and TG Therapeutics each gave investors reasons for cheer in the last few days.
TG Therapeutics May Have Potential but the Charts Need More Work
Shares of this biotech company are up 75% for 2019, despite recent weakness.
3 Promising Small Biotech Stocks to Watch
I think there is still upside left in a variety of smaller names especially if M&A activity picks up across the industry.
Keep Your Eye on the Oncology Sector Among Biotech Stocks
The myriad names in oncology have been the hottest area for acquisitions along with gene therapy.
Celebrating the Greatness of Individual Traders
Good individual traders will produce returns far in excess of anything that traditional Wall Street will earn.
3 Recent Big Gainers Kick Off the Dramatic Return of 'Small-Cap Friday'
Small-caps have done better than their bigger brethren so far in 2019, and these three stocks are a reason why.
How I See Biotechs Now
I expect deal volume to have a substantial uptick before the end of 2018 rolls around.
These 2 Biotech Stocks Still Have Upside
The biotech sector has seen a big rally, but there are still opportunities.
Biotech M&A: Who's Next After Gilead-Kite?
Prospects for acquisition activity in the sector are improving.
Biotech Needs a Shot in the Arm
But there is hope, as the FDA has approved almost as many new compounds in 2017 as in all of 2016.
The Machines Are Sapping the Fun out of This Day
Historically, the day before a holiday often has a positive bias, but the algos have killed emotion.
Biotech Needs a Shot in the Arm
But there is hope, as the FDA has approved almost as many new compounds in 2017 as in all of 2016.
Shark Bites: There Wasn't Even a Dip to Buy
Action runs counter to pattern, leaving market players wondering what to do.
Don't Be Surprised If Dip Buyers Jump In on Any Pullback
We'll see what happens in the way of reaction to Trump's tax policy this afternoon, but if we sell off I'm likely going to be a buyer.
Desire to Add Exposure Leads Indices Higher
The fact that many traders weren't well-positioned for Monday's move up is helping to create one-way action this morning.
Could These 9 Drugs Gain FDA Approval in the Age of Trump?
Nine biotech and drug companies want FDA approval, but need changed standards to get it.
The 'Gnarly 9' Biotechs Will Test the FDA's Mettle
The firms all have drugs they want the feds to bend the rules to approve.
2 Biotechs to Watch Ahead of the Election
These 2 small-caps have strong pipelines and are becoming analyst darlings.
TG Therapeutics Looks Like a Healthy Play
Small biotech tanked on weak earnings, but still seems promising.
5 Small-Cap Favorites Are Moving on Up
Updates on smaller housing, retail and biotech plays recently mentioned on these pages.
Profiting on Small-Cap Biotech Earnings
Don't trade the headline numbers, but cash in on those traders that do.
Are Drug Stocks What's Ailing the Market?
This move in health care takes your breath away.
Market Closes Back Where It Started
Greece provides good news, but bulk of action wasn't intraday.
More Morning Musings
It appears based on the futures that the market's rally will continue today, at least at the open. Personally, I think investors are becoming complacent given what could unfold in Greece over the next week. Everyone seems to be betting that Europe w...
3 Biotechs That Are Worth Buying
Many of these stocks are off to the races.
Cramer: Bob Dylan Was Right
The answer is blowing in the currency headwind.
